News & Resources

2015 Press Releases

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts

Media Contact:
Erika Hackmann
Y&R PR
Phone: 212-303-2305
Email:Erika.Hackmann@yr.com

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
11/25/15Orexigen Therapeutics to Speak at the Piper Jaffray 27th Annual Healthcare ConferencePrinter Friendly Version
11/06/15Orexigen Therapeutics to Present at Credit Suisse 2015 Healthcare ConferencePrinter Friendly Version
11/05/15Orexigen Therapeutics Reports Financial and Business Results for the Third Quarter Ended September 30, 2015Printer Friendly Version
11/03/15Orexigen Announces Naltrexone/Bupropion Data Presentations at ObesityWeek 2015Printer Friendly Version
10/22/15Orexigen Therapeutics to Provide Business Update and Discuss Third Quarter 2015 Financial Results on November 5, 2015Printer Friendly Version
10/01/15Orexigen Announces Submission of Contrave® New Drug Application in South KoreaPrinter Friendly Version
09/23/15Orexigen Receives Payments Totaling $22 Million from U.S. and Korean PartnersPrinter Friendly Version
09/10/15Orexigen Raises $60 Million in Sale of Common Stock to BaupostPrinter Friendly Version
09/04/15Orexigen Therapeutics to Speak at the Wells Fargo Securities 2015 Healthcare ConferencePrinter Friendly Version
08/06/15Orexigen Therapeutics Reports Financial and Business Results for the Second Quarter Ended June 30, 2015Printer Friendly Version
08/06/15Orexigen Announces Korean Distributorship Agreement with Kwang Dong Pharmaceutical CompanyPrinter Friendly Version
08/06/15Orexigen and Takeda Announce an Amended and Restated Collaboration AgreementPrinter Friendly Version
07/24/15Orexigen Therapeutics to Provide Business Update and Discuss Second Quarter 2015 Financial Results on August 6, 2015Printer Friendly Version
06/18/15Orexigen Therapeutics to Speak at the JMP Securities Life Sciences ConferencePrinter Friendly Version
06/05/15Orexigen Announces Upcoming Data Presentations from the Open-Label Contrave® Ignite Study at the Annual Meeting of the American Diabetes AssociationPrinter Friendly Version
06/05/15Orexigen and Takeda File Lawsuit Against Actavis for Infringement of Contrave® PatentsPrinter Friendly Version
05/12/15Takeda Pharmaceuticals and Orexigen Therapeutics Announce Termination of the Cardiovascular Outcomes Study (Light Study) of the Obesity Drug Contrave® (naltrexone HCl and bupropion HCl)Printer Friendly Version
05/12/15Orexigen Therapeutics Provides Statement on Termination of the Light Study and Updates on Contrave Collaboration with Takeda PharmaceuticalsPrinter Friendly Version
05/08/15Orexigen Therapeutics Reports Financial and Business Results for the First Quarter Ended March 31, 2015Printer Friendly Version
05/08/15Orexigen Therapeutics to Speak at the Bank of America Merrill Lynch Health Care ConferencePrinter Friendly Version
05/05/15Orexigen Therapeutics to Host First Quarter 2015 Financial Results Conference CallPrinter Friendly Version
04/22/15Orexigen Announces Receipt of Paragraph IV Certification NoticePrinter Friendly Version
04/10/15Orexigen Therapeutics to Speak at the Needham Healthcare ConferencePrinter Friendly Version
03/30/15Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial OfficerPrinter Friendly Version
03/26/15Orexigen's Mysimba™ Approved in Europe for the Treatment of ObesityPrinter Friendly Version
02/25/15Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2014Printer Friendly Version
02/23/15Orexigen Therapeutics to Speak at the 2015 RBC Capital Markets Global Healthcare ConferencePrinter Friendly Version
02/20/15Orexigen Therapeutics to Host Full Year and Fourth Quarter 2014 Financial Results Conference Call and WebcastPrinter Friendly Version
02/09/15Orexigen Provides Progress Update on Mysimba European Marketing AuthorizationPrinter Friendly Version
02/06/15Orexigen Therapeutics to Speak at the Leerink Global Healthcare ConferencePrinter Friendly Version
01/08/15Orexigen Therapeutics to Present at the J.P. Morgan 2015 Healthcare ConferencePrinter Friendly Version